Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A T C Chan

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Oncogene|July 25, 2006
The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formationT J Seng, J S W Low, H Li, et al.
Investigational New Drugs|June 19, 2015
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)B B Y Ma, B C Goh, W T Lim, et al.
British Journal of Cancer|March 3, 2011
Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patientsS C C Wong, S S M Ng, M T Cheung, et al.
Oncogene|May 13, 2008
Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomasK Y Lee, H Geng, K M Ng, et al.
Cancer Chemotherapy and Pharmacology|June 20, 2006
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)W Yeo, M Boyer, H C Chung, et al.
AJNR. American Journal of Neuroradiology|March 19, 2020
Early Detection of Cancer: Evaluation of MR Imaging Grading Systems in Patients with Suspected Nasopharyngeal CarcinomaA D King, J K S Woo, Q-Y Ai, et al.
Oncogene|November 9, 2010
Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell deathV W Y Lui, E Y L Wong, K Ho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trialA T C Chan, P M L Teo, R K Ngan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2019
Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinomaA D King, J K S Woo, Q Y Ai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2022
Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasmaD C T Chan, W K J Lam, E P Hui, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Oncogene|July 25, 2006
The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formationT J Seng, J S W Low, H Li, et al.
Investigational New Drugs|June 19, 2015
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)B B Y Ma, B C Goh, W T Lim, et al.
British Journal of Cancer|March 3, 2011
Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patientsS C C Wong, S S M Ng, M T Cheung, et al.
Oncogene|May 13, 2008
Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomasK Y Lee, H Geng, K M Ng, et al.
Cancer Chemotherapy and Pharmacology|June 20, 2006
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)W Yeo, M Boyer, H C Chung, et al.
AJNR. American Journal of Neuroradiology|March 19, 2020
Early Detection of Cancer: Evaluation of MR Imaging Grading Systems in Patients with Suspected Nasopharyngeal CarcinomaA D King, J K S Woo, Q-Y Ai, et al.
Oncogene|November 9, 2010
Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell deathV W Y Lui, E Y L Wong, K Ho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trialA T C Chan, P M L Teo, R K Ngan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2019
Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinomaA D King, J K S Woo, Q Y Ai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2022
Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasmaD C T Chan, W K J Lam, E P Hui, et al.
Pageof 5